Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02719613 · ClinicalTrials.gov registry record · Phase 2
Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab
A Phase 2 study of Multiple Myeloma, sponsored by Bristol-Myers Squibb.
- Active
- Registry status
- Phase 2
- Development phase
- 67
- Enrollment target
- 20
- Study locations
NCT02719613 is a Phase 2 study of Multiple Myeloma that is active but no longer recruiting, run by Bristol-Myers Squibb. The registered enrollment target is 67 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (88% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT02719613, a Phase 2 study of Multiple Myeloma, is active but no longer recruiting, sponsored by Bristol-Myers Squibb.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 67 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to continue to provide elotuzumab and/or other study drugs to participants who have participated on a prior protocol investigating elotuzumab who are not able to receive commercial drug supply.
Conditions Studied
Interventions
- DRUG Dexamethasone
- DRUG Lenalidomide
- DRUG Bortezomib
- DRUG Elotuzumab
Study Locations (20)
Other
- Local Institution - 0023 - Antwerp
- Local Institution - 0010 - Halifax
- Local Institution - 0035 - Athens
- Local Institution - 0036 - Budapest
California
- Local Institution - 0017 - Bakersfield
- Local Institution - 0022 - Fountain Valley
- Local Institution - 0016 - West Hollywood
Florida
- Local Institution - 0021 - Jacksonville
- Local Institution - 0042 - St. Petersburg
Arizona
- Local Institution - 0020 - Tucson
Colorado
- Local Institution - 0019 - Denver
Georgia
- Local Institution - 0009 - Atlanta
Indiana
- Local Institution - 0003 - Indianapolis
Massachusetts
- Local Institution - 0002 - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2016-07-15 |
| Est. Completion | 2025-11-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02719613
The ClinicalTrials.gov registry entry for NCT02719613 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (88% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 4 interventions - of which Dexamethasone is the first listed.
NCT02719613 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Other, California, Florida.
Frequently Asked Questions
What is clinical trial NCT02719613 about?
NCT02719613 is a clinical study titled "Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab". The purpose of this study is to continue to provide elotuzumab and/or other study drugs to participants who have participated on a prior protocol investigating elotuzumab who are not able to receive commercial drug supply.
What is the current status of trial NCT02719613?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 67 participants. The study started on 2016-07-15. Estimated completion is 2025-11-13.
What conditions does trial NCT02719613 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT02719613?
The interventions under investigation include: Dexamethasone (DRUG), Lenalidomide (DRUG), Bortezomib (DRUG), Elotuzumab (DRUG).
Who is sponsoring clinical trial NCT02719613?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02719613 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 2
-
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
CAR T-cell Therapy in Patients With Renal Dysfunction
RECRUITING · Phase 2
-
IMMUNOPLANT for Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.